Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

On Tuesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.58 which represents a decrease of $-2.15 or -2.13% from the prior close of $100.73. The stock opened at $100.76 and touched ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom Broadcom ... citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...

Merck’s MRK stock has declined 14.4% in ... Let’s understand these factors in detail to better analyze how to play the stock ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Today, Merck's forward price to sales ratio is ~5x ... the market sold off Merck stock, which fell in value by nearly 10% overnight. The above guidance was downgraded from Q1, when management ...